This page shows the latest Cancer therapy news and features for those working in and with pharma, biotech and healthcare.
AbbVie and Genmab’s blood cancer therapy, Epkinly (epcoritamab-bysp), has been granted accelerated approval by the US Food and Drug Administration (FDA). ... The partners outlined that they are evaluating Epkinly as a monotherapy, and in combination,
Researchers believe that uridine could also help fuel other cancers including lung, stomach and brain cancer. ... Team leader in systems and precision cancer medicine at the ICR, London, Dr Anguraj Sadanandam, said: “Next, we will explore ways to use
The combination therapy is specifically indicated for adults with advanced or recurrent endometrial cancer whose disease has progressed on or after platinum-based chemotherapy and who cannot have curative surgery or ... Professor Peter Johnson, NHS
The treatments, both given as one-off infusions, have been specifically recommended for use within the Cancer Drugs Fund (CDF), which pays for cancer treatments while further data is collected on ... Data supporting the use of the therapy was observed in
ADCs are a class of potent cancer therapies combining the selectivity of antibodies with the potent cell-killing properties of chemotherapy or other anti-cancer agents. ... Emma Lees, senior vice president, research and early development and head,
The US Food and Drug Administration (FDA) has approved Gamida Cell’s Omisirge (omidubicel-onlv) cell therapy to reduce the risk of infection following stem cell transplantation in blood cancer patients. ... Peter Marks, director of the FDA’s Center
More from news
Approximately 2 fully matching, plus 526 partially matching documents found.
By Brian Huber and Tamie Joeckel. Chimeric antigen receptor (CAR-T) cell therapy is a recent achievement in cancer therapy resulting in cures in several hard-to-treat blood cancers, including ... large B-cell lymphoma, acute lymphoblastic leukaemia and
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... targets of small cell lung
There was no robust, regulatory control but that has changed and any cell therapy now has to be properly approved.”. ... Tightening up regulatory policies was vital in order to move on from the cell therapy lowlight that saw a 21-year-old student die
and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer
More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
transplantation. He joins from ZMKS International Cancer Therapy Biotechnologies, a Chinese immuno-oncology company, where he served as chief scientific officer and director of research and development.
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.
protect us from infectious diseases – to recognise and kill cancer cells. ... Atir achieved some extremely compelling clinical data and the phase II study interim analysis in December demonstrated the drug's true potential as an adjunctive life-saving
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
The emergence of drugs with higher selectivity or specificity to pharmacological targets has altered the landscape of cancer therapy, and modern medicine as a whole. ... References. NICE. BNF. Cytotoxic Drugs. Available at: . Accessed November 2022.
This partnership, along with the additional Oncology Outcomes partners, provides Life Sciences Companies (LSCs) with a comprehensive body of evidence to support new anti-cancer therapy clinical development programs.”.
iii] Lobo R.A. Hormone-replacement therapy: Current thinking. Nat. Rev. Endocrinol. 2017; 13:220–231. ... iv] Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study.
Ovarian cancer – novel therapeutic approaches. Cancer Therapy Advisor 2017. Available at: https://www.cancertherapyadvisor.com/obstetrics-and-gynecology/ovarian-cancer-novel-therapeutic-approaches/article/617855/. ... Accessed April 2019. 8. Target
This year’s theme focused on securing access to optimal cancer care – a poignant topic and one that resonates across the healthcare sector, impacting patients in all walks of life. ... Ipsen Group developed an eye-catching attraction to offset this
More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...